Schizophrenia is a severe mental illness that interferes with a person's ability to think clearly, manage emotions, make decisions, and relate to others. It is a complex, long-term medical illness, affecting about one percent of Americans.
According to DelveInsight, majority of the Schizophrenia cases are males in the US and EU5. However, in Japan, females represent the majority of the diagnosed cases. The present Schizophrenia treatment goals include symptom targeting and relapse prevention, with no cure at hand.
Through the Schizophrenia newsletter, DelveInsight brings a brief picture of the mental disorder, Schizophrenia, its symptoms, signs, causes and diagnosis. Know more about the treatment landscape, unmet needs, and key companies working to advance the growth of the Schizophrenia market. Get a sneak-peek into the recent happenings on the research front, and key collaborations taking place in the domain.
Get access to our newsletter by filling up a simple form towards your tight.
Subscribe to our newsletter series and get the latest delivered right into your inbox.
Stay connected for more!
#DelveInsight, through its newsletter series, aims for increased awareness about the indication, its underlying causes, etiology, symptoms, and risk factors among its readers.
Have a copy of newsletter- https://www.delveinsight.com/whitepaper-newsletter/schizophrenia-newsletter
Know More About What's Covered:
· Indication overview
· Epidemiological trends
· Treatment approaches
· Pipeline drugs
· Key Companies
· R&D in the field
Have a copy of newsletter- https://www.delveinsight.com/whitepaper-newsletter/schizophrenia-newsletter
#raredisease #rare #disease #medicalsciences #newsletter #promotion #covid19 #healthcare #business # schizophrenia #readerscommunity #readinglist #newsletterdesign
Comments
Post a Comment